Measuring progesterone receptor expression to improve hormone-receptor-positive cancer managementMay 03, 2012
American and Spanish researchers have found potential ways for doctors to improve the treatment of hormone receptor-positive breast cancer even if they lack access to costly multi-gene tests, as they report at the 4th IMPAKT Breast Cancer Conference.
Because breast cancer is a biologically and clinically varied disease, doctors aim to choose appropriate treatments based on the characteristics of each patient's individual tumor. In the past, this has been done using pathology-based biomarkers; however these do not capture the full diversity of cancers.
"In this context, tests based on multi-gene expression have been shown to provide valuable information beyond the pathology-based biomarkers," says Dr Aleix Prat from the University of North Carolina, Chapel Hill. "However, multi-gene tests are not readily available in most of the world due to cost, assay turnaround times and other logistic issues."
Dr Prat and colleagues addressed this problem by trying to improve the current pathology-based biomarkers to better represent data coming from a particular multi-gene test known as the PAM50 breast cancer intrinsic classifier.
"The PAM50 breast cancer intrinsic classifier identifies two major groups of hormonal receptor-positive breast cancer known as the Luminal A and Luminal B subtypes. These two molecular entities have different risks of relapse and responses to chemotherapy," Dr Prat said.
Alongside the development of this multi-gene assay, clinicians have devised pathology-based surrogate assays for the identification of both the Luminal A and Luminal B subtypes. "In the absence of multi-gene assays, the pathology-based assays are clinically valuable," Dr Prat explained. "However, we observed that the current pathology-based definitions of the Luminal A and Luminal B subtypes still show a 30-40% discordance rate compared to multi-gene tests such as the PAM50 breast cancer intrinsic classifier."
The researchers examined differences in gene expression patterns between Luminal A and Luminal B tumors using the PAM50 test. They also collected clinical-pathological features from 2,950 primary tumors across four independent studies. Using statistical methods, they tested the independent prognostic significance of those features.
They found that the expression of progesterone receptor was one of the most discriminatory molecules. "Addition of quantitative scoring of the progesterone receptor into the current pathology-based Luminal A definition appears to better identify the subgroup of patients that have an outstanding survival when treated with endocrine therapy alone, and therefore do not need systemic chemotherapy," Dr Prat said. "This subpopulation of patients is likely to represent around 30% of the patients with low-risk pathology-defined Luminal A tumors."
"Current pathology-based definitions of the Luminal A and Luminal B subtypes are valuable, but can be improved for the management of hormonal receptor-positive breast cancer," the researcher concluded. "We believe that we have an improvement based upon the progesterone receptor, and given that progesterone receptor is widely used, our improvement could be widely and quickly adopted, if further validated."
According to Dr Di Leo, Hospital of Prato, Italy, former IMPAKT Chair, this is an important study with practical implications, because it tells us that the evaluation of the progesterone receptor along with the evaluation of other biomarkers, such as the estrogen receptor, proliferation markers and c-erbB2, may be relevant to better define the biological profile of the tumor. "This is a critical step towards a personalized medicine approach in breast cancer. It will be important to test the progesterone receptors according to a standardized approach across the pathology departments. One potential concern, in fact, could be the use of different techniques for the progesterone receptors evaluation, which might lead to discordant results between different pathology labs."
European Society for Medical Oncology
Related Breast Cancer Current Events and Breast Cancer News Articles
21-gene recurrence score and receipt of chemotherapy in patients with breast cancer
Use of the 21-gene recurrence test score was associated with lower chemotherapy use in high-risk patients and greater use of chemotherapy in low-risk patients compared with not using the test among a large group of Medicare beneficiaries, according to an article published online by JAMA Oncology.
Stiffer breast tissue in obese women promotes tumors
Women who are obese have a higher risk and a worse prognosis for breast cancer, but the reasons why remain unclear.
Use of tamoxifen by young women is influenced by fertility concerns
The risk of breast cancer recurrence and mortality is decreased by endocrine therapy (ET) such as tamoxifen, but younger patients may decline it or discontinue treatment early if they are concerned about fertility, according to a study published August 24 in the JNCI: Journal of the National Cancer Institute.
Blood vessel cells help tumours evade the immune system
A study by researchers at Sweden's Karolinska Institutet is the first to suggest that cells in the tumour blood vessels contribute to a local environment that protects the cancer cells from tumour-killing immune cells.
Study examines breast cancer mortality after ductal carcinoma in situ diagnosis
Researchers estimate the 20-year breast cancer-specific death rate for women diagnosed with ductal carcinoma in situ to be 3.3 percent, although the death rate is higher for women diagnosed before age 35 and for black women.
Ductal carcinoma in situ carries a higher risk of death than previously thought
Women diagnosed with ductal carcinoma in situ (DCIS) are twice as likely to die from breast cancer compared to the general U.S. population, according to a new study led by Dr. Steven Narod.
Tool boosts accuracy in assessing breast cancer risk
A national risk model that gauges a woman's chance of developing breast cancer has been refined to give a more accurate assessment.
Light/moderate drinking linked to increased risk of some cancers in women & male smokers
Even light and moderate drinking (up to one drink a day for women and up to two drinks a day for men) is associated with an increased risk of certain alcohol related cancers in women and male smokers, suggests a large study published by The BMJ today.
Drinking coffee daily may improve survival in colon cancer patients
Regular consumption of caffeinated coffee may help prevent the return of colon cancer after treatment and improve the chances of a cure, according to a new, large study from Dana-Farber Cancer Institute that reported this striking association for the first time.
First-of-its-kind study finds music therapy lowers anxiety during surgical breast biopsies
A first-of-its-kind study published in the Journal of Clinical Oncology finds that music therapy lessened anxiety for women undergoing surgical breast biopsies for cancer diagnosis and treatment. The two-year study out of University Hospitals Seidman Cancer Center involved 207 patients.
More Breast Cancer Current Events and Breast Cancer News Articles